Your search returned 2 results.

Results
	1.	Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor. [electronic resource] by Yingling, Jonathan M McMillen, William T Yan, Lei Huang, Huocong Sawyer, J Scott Graff, Jeremy Clawson, David K Britt, Karen S Anderson, Bryan D Beight, Douglas W Desaiah, Durisala Lahn, Michael M Benhadji, Karim A Lallena, Maria J Holmgaard, Rikke B Xu, Xiaohong Zhang, Faming Manro, Jason R Iversen, Philip W Iyer, Chandrasekar V Brekken, Rolf A Kalos, Michael D Driscoll, Kyla E Publication details: Oncotarget Jan 2018 In: Oncotarget vol. 9 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	A novel CDK9 inhibitor shows potent antitumor efficacy in preclinical hematologic tumor models. [electronic resource] by Yin, Tinggui Lallena, Maria J Kreklau, Emiko L Fales, Kevin R Carballares, Santiago Torrres, Raquel Wishart, Graham N Ajamie, Rose T Cronier, Damien M Iversen, Phillip W Meier, Timothy I Foreman, Robert T Zeckner, Douglas Sissons, Sean E Halstead, Bart W Lin, Aimee B Donoho, Gregory P Qian, Yuewei Li, Shuyu Wu, Song Aggarwal, Amit Ye, Xiang S Starling, James J Gaynor, Richard B de Dios, Alfonso Du, Jian Producer: 20150219 In: Molecular cancer therapeutics vol. 13 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)

Refine your search